This information is for healthcare professionals based in EU countries only.
Are you a healthcare professional?
Home
For your hATTR patients, what matters is now
Tegsedi can significantly delay disease progression, and it is the first subcutaneous treatment to target the disease at its source.1
With Tegsedi, patients have the independence to self-administer at a time and place that works for them.1
For your hATTR patients with stage 1 or 2 polyneuropathy. The priority isn’t only what lies ahead. It’s defending what is still here.
Learn more
References
- Tegsedi Summary of Product Characteristics. June 2021. 2. Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.